Program
solriamfetol
Also written as “JZP-110”, “Solriamfetol” and “Solriamfetol 300 mg”.
Its studies are mostly in Narcolepsy · Attention Deficit Disorder with Hyperactivity · Sleep Apnea, Obstructive · Depressive Disorder, Major · Disorders of Excessive Somnolence, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Axsome Therapeutics | 117 open or running | phase 4since Feb 25, 2021 | Feb 25, 2021 | Dec 2026phase 3 · NCT06413433 |
| Jazz Pharmaceuticals | 90 open or running | phase 3since Jan 15, 2015 | Dec 2, 2011 | none ahead |
| Ignis Therapeutics (Suzhou) | 10 open or running | phase 3since Sep 27, 2023 | Sep 27, 2023 | none ahead |
| Johnson & Johnson | 10 open or running | phase 2since Nov 17, 2003 | Nov 17, 2003 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 17, 2003.
- Jan 15, 20154 phase 3 studiesJazz Pharmaceuticals · NCT02348632, NCT02348619, NCT02348606 and 1 more
- Jun 10, 20162 phase 2 studiesJazz Pharmaceuticals · NCT02806908, NCT02806895
- Jan 23, 2017Phase 2 study in Disorders of Excessive SomnolenceJazz Pharmaceuticals · NCT03037203 · 66 enrolled · United States
- Feb 25, 2021Axsome Therapeutics's first study: phase 4 study in Disorders of Excessive SomnolenceNew to Axsome TherapeuticsAxsome Therapeutics · NCT04789174 · 59 enrolled · United States, Canada, Italy and more
- Aug 10, 2021Phase 1 study in NarcolepsyAxsome Therapeutics · NCT05008341 · 6 enrolled · United States
- Jul 25, 2023Phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT05972044 · 516 enrolled · United States
- Sep 27, 2023Ignis Therapeutics (Suzhou)'s first study: phase 3 study in Sleep Apnea, ObstructiveNew to Ignis Therapeutics (Suzhou)Ignis Therapeutics (Suzhou) · NCT06103825 · 204 enrolled · China
- Apr 8, 2024Phase 3 study in Depressive Disorder, MajorAxsome Therapeutics · NCT06360419 · 346 enrolled · United States
- May 9, 2024Phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06413433 · 450 planned · United States
- Aug 21, 2024Phase 3 study in Disorders of Excessive SomnolenceAxsome Therapeutics · NCT06568367 · 520 planned · United States, Canada
- Mar 14, 2025Phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06878976 · 236 planned · United States
- Mar 16, 2026Phase 3 study in Depressive Disorder, MajorAxsome Therapeutics · NCT07484217 · 508 planned · United States
- Jul 16, 20262 phase 3 studies in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07717892, NCT07717879
- Aug 14, 2026Phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07773883 · 300 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Disorders of Excessive SomnolenceAxsome Therapeutics · NCT06568367
- Dec 2026Primary completion: phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06413433
- Dec 2027Primary completion: phase 3 study in Attention Deficit Disorder with HyperactivityAxsome Therapeutics · NCT07773883
- Dec 2027Primary completion: phase 3 study in Binge-Eating DisorderAxsome Therapeutics · NCT06878976
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07773883Attention Deficit Disorder with Hyperactivity · United States | 3 | By invitation | Axsome Therapeutics | Dec 2027 | 300 |
| NCT07717892Attention Deficit Disorder with Hyperactivity · United States | 3 | Recruiting | Axsome Therapeutics | Jun 30, 2028 | 468 |
| NCT07717879Attention Deficit Disorder with Hyperactivity · United States | 3 | Recruiting | Axsome Therapeutics | Jun 30, 2028 | 468 |
| NCT07484217Depressive Disorder, Major · United States | 3 | Recruiting | Axsome Therapeutics | Dec 2028 | 508 |
| NCT06878976Binge-Eating Disorder · United States | 3 | By invitation | Axsome Therapeutics | Dec 2027 | 236 |
| NCT06568367Disorders of Excessive Somnolence · United States, Canada | 3 | Recruiting | Axsome Therapeutics | Dec 2026 | 520 |
| NCT06413433Binge-Eating Disorder · United States | 3 | Recruiting | Axsome Therapeutics | Dec 2026 | 450 |
| NCT06360419Depressive Disorder, Major · United States | 3 | Completed | Axsome Therapeutics | Dec 31, 2024 | 346 |
| NCT06103825Sleep Apnea, Obstructive · China | 3 | Completed | Ignis Therapeutics (Suzhou) | Jul 20, 2024 | 204 |
| NCT05972044Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Axsome Therapeutics | Feb 7, 2025 | 516 |
| NCT05008341Narcolepsy · United States | 1 | Completed | Axsome Therapeutics | Apr 15, 2022 | 6 |
| NCT04789174Disorders of Excessive Somnolence · United States, Canada, Italy and more | 4 | Completed | Axsome Therapeutics | Sep 19, 2022 | 59 |
| NCT03037203Disorders of Excessive Somnolence · United States | 2 | Completed | Jazz Pharmaceuticals | Aug 2018 | 66 |
| NCT02806908Narcolepsy · Netherlands | 2 | Completed | Jazz Pharmaceuticals | May 19, 2019 | 24 |
| NCT02806895Sleep Apnea, Obstructive · Netherlands | 2 | Completed | Jazz Pharmaceuticals | May 28, 2019 | 34 |
| NCT02348632Narcolepsy · United States, Canada, Finland and more | 3 | Completed | Jazz Pharmaceuticals | Dec 2017 | 645 |
| NCT02348619Sleep Apnea, Obstructive · United States, Finland, France and more | 3 | Completed | Jazz Pharmaceuticals | Nov 2016 | 174 |
| NCT02348606Sleep Apnea, Obstructive · United States, Canada, France and more | 3 | Completed | Jazz Pharmaceuticals | Dec 2016 | 476 |
| NCT02348593Narcolepsy · United States, Canada, Finland and more | 3 | Completed | Jazz Pharmaceuticals | Feb 2017 | 239 |
| NCT01681121Narcolepsy · United States | 2 | Completed | Jazz Pharmaceuticals | Aug 2013 | 93 |
| NCT01485770Narcolepsy · United States | 2 | Completed | Jazz Pharmaceuticals | May 2012 | 33 |
| NCT00073203Depressive Disorder, Major · United States | 2 | Completed | Johnson & Johnson | 488 |
How it is read
Names in the registry
- “JZP-110”, 7 entries
- “Solriamfetol”, 4 entries
- “Solriamfetol 300 mg”, 4 entries
- “Solriamfetol 150 mg”, 3 entries
- “Solriamfetol Dose A”, 2 entries
Conditions, from the studies’ own filings
- Narcolepsy, 6 studies
- Attention Deficit Disorder with Hyperactivity, 4 studies
- Sleep Apnea, Obstructive, 4 studies
- Depressive Disorder, Major, 3 studies
- Disorders of Excessive Somnolence, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.